Paris, France – January 2026 – Plantibodies, a biotechnology company developing plant-based oral immunotherapies designed to act locally in the gastrointestinal tract, today announced the completion of a €500,000 equity financing backed by three recognized French business angel groups: Angels Santé, BAdGE (Business Angels des Grandes Écoles), and Investessor.
Plantibodies’ technology leverages plants as both a bioproduction and oral delivery system for biologics, enabling targeted activity directly within the gastrointestinal tract. This approach aims to address key limitations of injectable biologics, including systemic exposure, tolerability issues, and high manufacturing costs, particularly in chronic gastrointestinal diseases with significant unmet medical need.
Financing to support proprietary programs and strategic partnerships
The funds raised will support the development of Plantibodies’ own pipeline of oral immunotherapies, while also enabling the execution of an ongoing strategic co-development partnership with a Nasdaq-listed biotechnology company, signed in the second half of 2025. These two activities are complementary and reflect the company’s dual strategy of advancing internal assets while validating its platform through industrial collaborations.
In parallel, a part of the work supported by this financing will focus on oral formulation development and CMC (Chemistry, Manufacturing and Controls). This includes optimizing the stability, reproducibility, and scalability of plant-expressed biologics, with the objective of enabling robust preclinical development and future clinical translation, while facilitating industrialization.
In addition, the financing will be used to support continued business development efforts with pharmaceutical and biotechnology partners.
A differentiated approach to gastrointestinal diseases
By enabling local activity of biologics directly within the gastrointestinal tract, Plantibodies’ approach is designed to address key challenges associated with chronic gastrointestinal diseases. These include the need for long-term treatment, limitations related to systemic exposure, and constraints on patient adherence. Localized oral immunotherapies have the potential to improve therapeutic outcomes while offering a more convenient and better-tolerated treatment option for patients with debilitating gastrointestinal conditions.
Management comment
“This financing strengthens our ability to execute with discipline and to reach the next key milestones for Plantibodies. It allows us to advance our proprietary programs, deliver on our strategic partnership, and reinforce our manufacturing and CMC foundations, while remaining fully focused on our primary objective: delivering meaningful clinical impact for patients through oral immunotherapies.”
— Pierre BAUËR, CEO and Co-founder
About Plantibodies
Plantibodies is a French biotechnology company developing next-generation oral immunotherapies based on plant-expressed biologics. The company focuses on gastrointestinal diseases, with the ambition to deliver localized, well-tolerated, and scalable therapeutic solutions addressing significant unmet medical needs.
About the investors
Angels Santé is a leading French business angel network dedicated to healthcare and life sciences, supporting innovative companies from early stages through growth.
BAdGE brings together entrepreneurs and executives from top French Grandes Écoles, investing in high-potential technology and life-science startups.
🌐 http://www.business-angels.info
Investessor is an early-stage investment network supporting innovative startups with strong technological differentiation.
Press contacts:
Plantibodies
Pierre Bauër – CEO
📧 pierre.bauer@plantibodies.tech
BAdGE (Business Angels des Grandes Écoles)
Corentin Gaudelot – Managing Director
📧 corentin.gaudelot@business-angels.info
📞 +33 (0)1 42 22 67 35
Angels Santé
Press & Communications
📧 info@angelssante.fr
Investessor
Press & Communications
📧 contact@investessor.com